IL17A and psoriasis: Emerging evidence from clinical trials has shown that monoclonal antibodies to IL-23, IL-17, and TNF are effective in treating patients with psoriasis, atopic dermatitis, pyoderma, rosacea, pemphigus, and scleroderma systemic [80].